Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study

The Lancet

Volumn 371, Issue 9618, 2008, Pages 1108-1113

  von Gottberg, Anne ^a,b,d   Klugman, Keith P ^a,b,d,e   Cohen, Cheryl ^a,c   Wolter, Nicole ^a,b,d   de Gouveia, Linda ^a,d   du Plessis, Mignon ^a,b,d   Mpembe, Ruth ^a,d   Quan, Vanessa ^a   Whitelaw, Andrew ^f,g   Hoffmann, Rena ^f,h   Govender, Nelesh ^a,b   Meiring, Susan ^a   Smith, Anthony M ^a,b   Schrag, Stephanie ⁱ  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e EMORY UNIVERSITY   (United States)

^f NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h STELLENBOSCH UNIVERSITY   (South Africa)

ⁱ NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE; RIFAMPICIN; TETRACYCLINE;

ADOLESCENT; ARTICLE; BACTERIUM ISOLATE; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE CONTROL; FEMALE; HISTORY; HOSPITAL; HOSPITAL INFECTION; HUMAN; INFANT; LABORATORY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MULTIDRUG RESISTANCE; NASOPHARYNX; NEWBORN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; SCREENING; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS; UNITED STATES;

EID: 40949105392     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60350-5     Document Type: Article

References (39)

1. Appelbaum P., Bhamjee A., Scragg J., Hallett A., Bowen A., and Cooper R. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 2 (1977) 995-997
2. Jacobs M., Koornhof H., Robins-Browne R., et al. Emergence of multiply resistant pneumococci. N Engl J Med 299 (1978) 735-740
3. Davidson R., Cavalcanti R., Brunton J., et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346 (2002) 747-750
4. Low D. Fluoroquinolone-resistant pneumococci: maybe resistance isn't futile?. Clin Infect Dis 40 (2005) 236-238
5. Anon. Resistance of Streptococcus pneumoniae to fluoroquinolones-United States, 1995-1999. MMWR Morb Mortal Wkly Rep 50 (2001) 800-804
6. Linares J., de la Campa A., and Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 341 (1999) 1546-1547
7. Chen D., McGeer A., de Azavedo J., and Low D. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 341 (1999) 233-239
8. Ho P., Tse W., Tsang K., et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 32 (2001) 701-707
9. Mandell L., Peterson L., Wise R., et al. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?. Clin Infect Dis 35 (2002) 721-727
10. von Gottberg A., Ludewick H., Bamber S., Govind C., Sturm A., and Klugman K. Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in a South African child in a tuberculosis treatment facility. Pediatr Infect Dis J 22 (2003) 1020-1021
11. Huang T., Avrain L., de B., and Glupczynski Y. Streptococcus pneumoniae clinical isolate highly resistant to fluoroquinolones in a child. Pediatr Infect Dis J 25 (2006) 1195-1196
12. Yew W., and Chau C. Utility of fluoroquinolones in multidrug-resistant tuberculosis (MDR-TB)-a balanced view?. Int J Tuberc Lung Dis 6 (2002) 174-175
13. Gosling R., and Gillespie S. Moxifloxacin treatment of tuberculosis. Antimicrob Agents Chemother 48 (2004) 3642-3643
14. Gandhi N., Moll A., Sturm A., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368 (2006) 1575-1580
15. Huebner R., Klugman K., Matai U., Eggers R., and Hussey G. Laboratory surveillance for Haemophilus influenzae type b, meningococcal, and pneumococcal disease. Haemophilus Surveillance Working Group. S Afr Med J 89 (1999) 924-925
16. O'Brien K., Bronsdon M., Dagan R., et al. Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol 39 (2001) 1021-1024
17. Ruoff K., Whiley R., and Beighton D. Streptococcus. In: Murray P., Baron E., Jorgensen J., Pfaller M., and Yolken R. (Eds). Manual of clinical microbiology. 8 edn. (2003), ASM Press, Washington, DC 405-421
18. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. CLSI document M100-S15 ed (2005), NCCLS, Wayne, Pennsylvania
19. Lefevre J., Faucon G., Sicard A., and Gasc A. DNA fingerprinting of Streptococcus pneumoniae strains by pulsed-field gel electrophoresis. J Clin Microbiol 31 (1993) 2724-2728
20. McEllistrem M., Stout J., and Harrison L. Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae. J Clin Microbiol 38 (2000) 351-353
21. Ho P., Que T., Chiu S., et al. Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001. Emerg Infect Dis 10 (2004) 1250-1257
22. Koornhof H., Wasas A., and Klugman K. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective. Clin Infect Dis 15 (1992) 84-94
23. Woolfson A., Huebner R., Wasas A., Chola S., Godfrey-Faussett P., and Klugman K. Nasopharyngeal carriage of community-acquired, antibiotic-resistant Streptococcus pneumoniae in a Zambian paediatric population. Bull World Health Organ 75 (1997) 453-462
24. Borer A., Meirson H., Peled N., et al. Antibiotic-resistant pneumococci carried by young children do not appear to disseminate to adult members of a closed community. Clin Infect Dis 33 (2001) 436-444
25. Nuorti J., Butler J., Farley M., et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 342 (2000) 681-689
26. Karstaedt A., Khoosal M., and Crewe-Brown H. Pneumococcal bacteremia in adults in Soweto, South Africa, during the course of a decade. Clin Infect Dis 33 (2001) 610-614
27. Buie K., Klugman K., von Gottberg A., et al. Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia. J Infect Dis 189 (2004) 1996-2000
28. McGee L., Goldsmith C., and Klugman K. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother 49 (2002) 173-176
29. Klugman K. The role of clonality in the global spread of fluoroquinolone-resistant bacteria. Clin Infect Dis 36 (2003) 783-785
30. Pletz M., McGee L., Jorgensen J., et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 48 (2004) 3491-3497
31. Adam H., Schurek K., Nichol K., et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother 51 (2007) 198-207
32. Fry A., Udeagu C., Soriano-Gabarro M., et al. Persistence of fluoroquinolone-resistant, multidrug-resistant Streptococcus pneumoniae in a long-term-care facility: efforts to reduce intrafacility transmission. Infect Control Hosp Epidemiol 26 (2005) 239-247
33. Carter R., Sorenson G., Heffernan R., et al. Failure to control an outbreak of multidrug-resistant Streptococcus pneumoniae in a long-term-care facility: emergence and ongoing transmission of a fluoroquinolone-resistant strain. Infect Control Hosp Epidemiol 26 (2005) 248-255
34. Klugman K. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect Dis 1 (2001) 85-91
35. Mbelle N., Huebner R., Wasas A., Kimura A., Chang I., and Klugman K. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 180 (1999) 1171-1176
36. Robinson K., Baughman W., Rothrock G., et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 285 (2001) 1729-1735
37. Gendrel D., Chalumeau M., Moulin F., and Raymond J. Fluoroquinolones in paediatrics: a risk for the patient or for the community?. Lancet Infect Dis 3 (2003) 537-546
38. Statistics South Africa. P0309.3-Mortality and causes of death in South Africa: findings from death notification, 2005. http://www.statssa.gov.za/publications/statsdownload.asp?PPN=P0309. 3&SCH=3937 (accessed July 9, 2007).
39. Corbett E., Marston B., Churchyard G., and De Cock K. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367 (2006) 926-937